|
Initiation
| ShowHide Related Items >><< - 11/11/22
- Nouveau Monde provides update on Panasonic partnership
- 10/20/22
- Nouveau Monde rises 7.7%
- 10/20/22
- Nouveau Monde, Mitsui and Panasonic enter offtake partnership
- 08/29/22
- Nouveau Monde falls -5.6%
- 10/27/22 B. Riley
- Nouveau Monde assumed with a Buy at B. Riley
- 09/01/22
- Tesla recently visited Nouveau Monde's graphite site in Quebec, Electrek says
|
|
Recommendations
| ShowHide Related Items >><< VRTX Vertex Pharmaceuticals - $308.78 /
+3.835 (+1.26%) - 02/07/23
- Vertex Pharmaceuticals board authorizes $3.0B buyback
- 01/11/23
- Vertex Pharmaceuticals expands collaboration with Arbor Biotechnologies
- 12/12/22
- FDA clears Vertex IND application for VX-522 to treat CF
- 12/08/22
- Vertex Pharmaceuticals, Entrada Therapeutics enter EEV therapeutics pact
VRTX Vertex Pharmaceuticals - $308.78 /
+3.835 (+1.26%) - 05:40 Today Barclays
- Vertex Pharmaceuticals price target raised to $342 from $313 at Barclays
- 01/19/23 Piper Sandler
- Vertex Pharmaceuticals price target raised to $296 from $293 at Piper Sandler
- 01/18/23 Canaccord
- Vertex Pharmaceuticals initiated with a Hold at Canaccord
- 01/17/23 SVB Securities
- SVB Securities upgrades Vertex to Outperform, raises price target to $374
VRTX Vertex Pharmaceuticals - $308.78 /
+3.835 (+1.26%) - 02/07/23
- Vertex Pharmaceuticals guides FY23 revenue $9.55B-$9.70B, consensus $9.6B
- 02/07/23
- Vertex Pharmaceuticals reports Q4 EPS $3.76, consensus $3.51
- 02/07/23
- Notable companies reporting after market close
- 10/27/22
- Vertex Pharmaceuticals raises 2022 revenue to $8.8B-$8.9B from $8.6B-$8.9B
VRTX Vertex Pharmaceuticals - $308.78 /
+3.835 (+1.26%) - 02/07/23
- Vertex keeps cystic fibrosis drug out of developing countries, NY Times reports
VRTX Vertex Pharmaceuticals - $308.78 /
+3.835 (+1.26%) - 12/30/22
- What You Missed On Wall Street This Morning
- 12/19/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 10/31/22
- Biotech Alert: Searches spiking for these stocks today
- 10/27/22
- Fly Intel: After-Hours Movers
VRTX Vertex Pharmaceuticals - $308.78 /
+3.835 (+1.26%) - 02/07/23
- Vertex options imply 3.7% move in share price post-earnings
- 11/28/22
- Early notable gainers among liquid option names on November 28th
- 09/16/22
- Early notable gainers among liquid option names on September 16th
- 09/01/22
- Early notable gainers among liquid option names on September 1st
|
|
Hot Stocks
| ShowHide Related Items >><< - 10/18/22
- Coherent appoints Julie Sheridan Eng as Chief Technology Officer
- 10/17/22
- Windstream partners with Coherent, Nokia for 400 Gig networking
- 09/16/22
- Coherent introduces ultrahigh-resolution telemetry module
- 09/15/22
- Coherent introduces 200G indium phosphide EMLs for datacenter transceivers
- 01/23/23 Barclays
- Coherent price target raised to $36 from $30 at Barclays
- 01/17/23 Rosenblatt
- Coherent initiated with a Buy at Rosenblatt
- 01/11/23 Craig-Hallum
- Lumentum price target lowered to $75 from $80 at Craig-Hallum
- 12/20/22 JPMorgan
- Coherent price target lowered to $52 from $74 at JPMorgan
- 11/09/22
- Coherent sees FY23 revenue $5.25B-$5.55B, consensus $5.43B
- 11/09/22
- Coherent sees Q2 adjusted EPS 88c-$1.00, consensus 94c
- 11/09/22
- Coherent reports Q1 adjusted EPS $1.04, consensus 83c
- 11/11/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/09/22
- What You Missed On Wall Street On Wednesday
- 11/09/22
- What You Missed On Wall Street This Morning
- 09/08/22
- Four new option listings and two option delistings on September 8th
|
|
Upgrade
| ShowHide Related Items >><< - 11/30/22
- TripAdvisor says Kanika Soni to leave position as Chief Commercial Officer
- 11/15/22
- TripAdvisor names John Boris as Chief Marketing Officer
- 11/08/22
- TripAdvisor: 'Premature' to provide 2023 outlook
- 11/08/22
- TripAdvisor: Travel remains 'robust'
- 12/07/22 Wolfe Research
- TripAdvisor downgraded to Underperform from Peer Perform at Wolfe Research
- 11/25/22 DA Davidson
- TripAdvisor price target lowered to $30 from $33 at DA Davidson
- 11/09/22 Wells Fargo
- TripAdvisor price target lowered to $22 from $30 at Wells Fargo
- 11/09/22 Mizuho
- TripAdvisor price target lowered to $22 from $26 at Mizuho
- 11/07/22
- TripAdvisor sees Q4 revenue of low-single digit increases from 2019 levels
- 11/07/22
- TripAdvisor reports Q3 adjusted EPS 28c, consensus 38c
- 11/07/22
- Notable companies reporting after market close
- 12/10/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 12/07/22
- What You Missed On Wall Street On Wednesday
- 12/07/22
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 11/08/22
- What You Missed On Wall Street On Tuesday
- 12/07/22
- TripAdvisor put volume heavy and directionally bearish
- 11/07/22
- TripAdvisor options imply 11.1% move in share price post-earnings
|
|
Hot Stocks
|
Perion Network announced… ShowHide Related Items >><< - 01/30/23 Needham
- Perion Network price target raised to $37 from $32 at Needham
- 01/20/23 Lake Street
- Lake Street 'comfortable' with revenue growth forecast for Perion Network
- 02/10/22 Oppenheimer
- Perion Network price target lowered to $30 from $35 at Oppenheimer
- 01/04/23
- Perion Network reports preliminary FY22 revenue $636M, consensus $632.26.6M
- 01/04/23
- Perion Network reports preliminary Q4 revenue $205M, consensus $201.6M
- 11/09/22
- Perion Network reports Q3 EPS 61c, consensus 43c
- 10/06/22
- Perion reports preliminary Q3 revenue $158M, consensus $155.4M
- 01/04/23
- What You Missed On Wall Street On Wednesday
- 01/04/23
- What You Missed On Wall Street This Morning
- 01/04/23
- Fly Intel: Pre-market Movers
- 10/06/22
- What You Missed On Wall Street On Thursday
- 12/09/22
- Largest borrow rate increases among liquid names
- 12/06/22
- Largest borrow rate increases among liquid names
- 11/25/22
- Largest borrow rate increases among liquid names
|
|
Recommendations
| ShowHide Related Items >><< - $174.77 /
+0.885 (+0.51%) - 01/31/23
- Target says Omaha West store closed until further notice following incident
- 01/09/23
- Mattel's Fisher-Price re-announces recall of 4.7M Rock 'n Play Sleepers
- 12/22/22
- Target recalls roughly 204,000 children's weighted blankets after two deaths
- 11/25/22
- Target announces Cyber Monday sales event from Nov. 27-28
- 02/07/23
- Bed Bath & Beyond: Default under credit agreement waived
- 02/07/23
- Bed Bath & Beyond has initiated incremental store closures
- 02/07/23
- Bed Bath & Beyond completes public equity offering
- 02/07/23
- Bed Bath & Beyond completes public equity offering, provides strategic update
- $174.77 /
+0.885 (+0.51%) - 02/07/23 Barclays
- Barclays sees a 'reset' in U.S. retail but 'not a recession yet'
- 02/07/23 Barclays
- Target initiated with an Equal Weight at Barclays
- 01/23/23 Oppenheimer
- Target initiated with an Outperform at Oppenheimer
- 01/04/23 Wells Fargo
- Wells Fargo downgrades Target to Equal Weight, lowers price target to $142
- 02/07/23 Odeon Capital
- Bed Bath & Beyond downgraded to Sell from Hold at Odeon Capital
- 02/07/23 Wedbush
- Wedbush cuts Bed Bath & Beyond target to 0c amid last effort to avoid bankruptcy
- 01/11/23 Wedbush
- Bed Bath & Beyond price target lowered to $1 from $5 at Wedbush
- 01/11/23 Baird
- Bed Bath & Beyond price target lowered to $1.00 from $2.00 at Baird
- $174.77 /
+0.885 (+0.51%) - 11/16/22
- Target on track to deliver total sales of well over $100B this year, says COO
- 11/16/22
- Target reports Q3 adjusted EPS $1.54, consensus $2.13
- 11/15/22
- Notable companies reporting before tomorrow's open
- 11/15/22
- Notable companies reporting before tomorrow's open
- 01/10/23
- Bed Bath & Beyond reports Q3 adjusted EPS ($3.65), consensus ($2.11)
- 01/05/23
- Bed Bath & Beyond sees Q3 net sales of about $1.26B, consensus $1.4B
- 09/29/22
- Bed Bath & Beyond reports Q2 adjusted EPS ($3.22), consensus ($1.85)
- 09/28/22
- Notable companies reporting before tomorrow's open
- $174.77 /
+0.885 (+0.51%) - 11/14/22
- Walmart taking 'aggressive' stance with suppliers, WSJ reports
- 10/15/22
- Shortages have turned to gluts, off-price retailers could benefit, Barron's says
- 09/03/22
- Target's problems won't last forever, time to buy stock, Barron's says
- 02/07/23
- Hudson Bay anchor investor of Bed Bath share sale, Bloomberg reports
- 02/02/23
- Bed Bath & Beyond misses interest payments, weighs Chapter 11, WSJ reports
- 01/31/23
- Bed Bath & Beyond prepares to seek bankruptcy protection, Reuters reports
- 01/29/23
- Bed Bath & Beyond to close 87 more stores, Harmon chain, WSJ reports
- $174.77 /
+0.885 (+0.51%) - 01/28/23
- Buy/Sell: Wall Street's top 10 stock calls this week
- 01/24/23
- What You Missed On Wall Street On Tuesday
- 01/24/23
- What You Missed On Wall Street This Morning
- 01/24/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 02/07/23
- What You Missed On Wall Street On Tuesday
- 02/07/23
- What You Missed On Wall Street This Morning
- 02/07/23
- Fly Intel: Pre-market Movers
- 02/06/23
- Fly Intel: After-Hours Movers
- $174.77 /
+0.885 (+0.51%) - 01/19/23
- Target put volume heavy and directionally bearish
- 01/06/23
- Early notable gainers among liquid option names on January 6th
- 01/06/23
- Unusually active option classes on open January 6th
- 11/28/22
- Early notable gainers among liquid option names on November 28th
- 02/07/23
- Notable open interest changes for February 7th
- 02/07/23
- Bed Bath & Beyond call buyer realizes 918% same-day gains
- 02/01/23
- Notable open interest changes for February 1st
- 01/27/23
- Notable open interest changes for January 27th
|
|
Earnings
| ShowHide Related Items >><< EPC Edgewell Personal Care - 12/16/22
- Edgewell Personal Care names Robert Schmidt as Chief Accounting Officer
- 09/15/22
- Edgewell Personal Care streamlines leadership and organizational structure
EPC Edgewell Personal Care - 11/16/22 Canaccord
- Canaccord starts Edgewell Personal Care at Buy amid men's 'beauty boom'
- 11/16/22 Canaccord
- Edgewell Personal Care initiated with a Buy at Canaccord
- 11/14/22 Barclays
- Edgewell Personal Care price target raised to $35 from $31 at Barclays
- 10/25/22 Goldman Sachs
- Edgewell downgraded to Neutral from Conviction Buy at Goldman Sachs
EPC Edgewell Personal Care - 11/10/22
- Edgewell Personal Care sees FY23 adjusted EPS $2.30-$2.50, consensus $2.56
- 11/10/22
- Edgewell Personal Care reports Q4 adjusted EPS 79c, consensus 76c
|
|
Earnings
| ShowHide Related Items >><< - $100.65 /
-0.835 (-0.82%) - 12/01/22
- Ingredion gets SBTi approval of its greenhouse gas emissions reduction targets
- 11/07/22
- Ingredion completes one-third of its $160M in capital investments
- 09/26/22
- Ingredion announces 6M share repurchase plan
- 09/26/22
- Ingredion increases quarterly dividend 9% to 71c per share
- $100.65 /
-0.835 (-0.82%) - 01/23/23 Barclays
- Ingredion downgraded to Equal Weight from Overweight at Barclays
- 01/17/23 Stephens
- Ingredion upgraded to Overweight from Equal Weight at Stephens
- 11/07/22 Credit Suisse
- Ingredion price target raised to $100 from $94 at Credit Suisse
- 09/30/22 UBS
- Ingredion initiated with a Neutral at UBS
- $100.65 /
-0.835 (-0.82%) - 06:06 Today
- Ingredion reports Q4 adjusted EPS $1.65, consensus $1.45
- 11/03/22
- Ingredion narrows FY22 adjusted EPS view to $7.00-$7.45 from $6.90-$7.45
- 11/03/22
- Ingredion reports Q3 adjusted EPS $1.73, consensus $1.62
- 08/09/22
- Ingredion sees FY22 adjusted EPS $6.90-$7.45, consensus $7.14
- $100.65 /
-0.835 (-0.82%) - 01/23/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 09/26/22
- Fly Intel: After-Hours Movers
|
|
Upgrade
| ShowHide Related Items >><< - 02/07/23
- Royal Caribbean jumps 5% to $72.54 after reporting Q4 results, FY23 guidance
- 02/07/23
- Royal Caribbean sees FY23 CapEx $4.1B
- 02/07/23
- Royal Caribbean 'very encouraged about the demand environment for 2023'
- 01/12/23
- Royal Caribbean amends, extends revolving credit facilities
- 05:34 Today Barclays
- Royal Caribbean price target raised to $88 from $74 at Barclays
- 04:44 Today Deutsche Bank
- Royal Caribbean price target raised to $65 from $62 at Deutsche Bank
- 01/31/23 Citi
- Royal Caribbean offers most value in cruise sector, says Citi
- 01/20/23 Deutsche Bank
- Royal Caribbean price target raised to $62 from $48 at Deutsche Bank
- 02/07/23
- Royal Caribbean sees FY23 adjusted EPS $3.00-$3.60, consensus $3.25
- 02/07/23
- Royal Caribbean sees Q1 adjusted EPS (85c)-(65c), consensus (80c)
- 02/07/23
- Royal Caribbean reports Q4 adjusted EPS ($1.12), consensus ($1.34)
- 11/03/22
- Royal Caribbean sees Q4 adjusted EPS ($1.50)-($1.30), consensus (67c)
- 08/17/22
- Royal Caribbean seeks approval to sail again in Hong Kong, SCMP reports
- 08/13/22
- Royal Caribbean among companies at risk of liquidity squeeze, Barron's says
- 02/07/23
- What You Missed On Wall Street On Tuesday
- 02/07/23
- What You Missed On Wall Street This Morning
- 01/10/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 12/10/22
- Buy/Sell: Wall Street's top 10 stock calls this week
- 02/07/23
- Early notable gainers among liquid option names on February 7th
- 02/07/23
- Unusually active option classes on open February 7th
- 01/19/23
- Royal Caribbean put volume heavy and directionally bearish
- 12/21/22
- Early notable gainers among liquid option names on December 21st
|
|
Earnings
| ShowHide Related Items >><< - $100.65 /
-0.835 (-0.82%) - 12/01/22
- Ingredion gets SBTi approval of its greenhouse gas emissions reduction targets
- 11/07/22
- Ingredion completes one-third of its $160M in capital investments
- 09/26/22
- Ingredion announces 6M share repurchase plan
- 09/26/22
- Ingredion increases quarterly dividend 9% to 71c per share
- $100.65 /
-0.835 (-0.82%) - 01/23/23 Barclays
- Ingredion downgraded to Equal Weight from Overweight at Barclays
- 01/17/23 Stephens
- Ingredion upgraded to Overweight from Equal Weight at Stephens
- 11/07/22 Credit Suisse
- Ingredion price target raised to $100 from $94 at Credit Suisse
- 09/30/22 UBS
- Ingredion initiated with a Neutral at UBS
- $100.65 /
-0.835 (-0.82%) - 11/03/22
- Ingredion narrows FY22 adjusted EPS view to $7.00-$7.45 from $6.90-$7.45
- 11/03/22
- Ingredion reports Q3 adjusted EPS $1.73, consensus $1.62
- 08/09/22
- Ingredion sees FY22 adjusted EPS $6.90-$7.45, consensus $7.14
- 08/09/22
- Ingredion reports Q2 adjusted EPS $2.12, consensus $1.94
- $100.65 /
-0.835 (-0.82%) - 01/23/23
- Street Wrap: Today's Top 15 Upgrades, Downgrades, Initiations
- 09/26/22
- Fly Intel: After-Hours Movers
|
